Lists & References
DEA Diversion Schedule I Drugs list
First Generation Antihistamines – sedative effects
First Generation AntiDepressants – sedative side effects
List of TCAs (Tricyclic Antidepressants – courtesy wikipedia)
Those that preferentially inhibit the reuptake of serotonin (by at least 10 fold over norepinephrine) include:
- Clomipramine (Anafranil) (~200× selective for serotonin over norepinephrine reuptake)
- Imipramine (Tofranil, Janimine, Praminil)
Those that preferentially inhibit the reuptake of norepinephrine (by at least 10 fold over serotonin) include:
- Desipramine (Norpramin, Pertofrane)
- Dibenzepin‡ (Noveril, Victoril)
- Lofepramine§ (Lomont, Gamanil)
- Nortriptyline (Pamelor, Aventyl, Norpress)
- Protriptyline (Vivactil)
Whereas fairly balanced serotonin-norepinephrine reuptake inhibitors include:
- Amitriptyline (Tryptomer, Elavil, Endep)
- Amitriptylinoxide (Amioxid, Ambivalon, Equilibrin)
- Amoxapine (Asendin) – can be classed with the tetracyclic antidepressants (TeCAs) but more frequently classed with the secondary amine TCAs.
- Butriptyline† (Evadyne)
- Demexiptiline† (Deparon, Tinoran)
- Dimetacrine† (Istonil, Istonyl, Miroistonil)
- Dosulepin§ (Prothiaden)
- Doxepin (Adapin, Sinequan)
- Imipraminoxide† (Imiprex, Elepsin)
- Melitracen§ (Deanxit, Dixeran, Melixeran, Trausabun)
- Metapramine† (Timaxel)
- Nitroxazepine‡ (Sintamil)
- Noxiptiline‡ (Agedal, Elronon, Nogedal)
- Pipofezine‡ (Azafen/Azaphen)
- Propizepine† (Depressin, Vagran)
- Quinupramine† (Kevopril, Kinupril, Adeprim, Quinuprine)
and the following are TCAs that act via other mechanisms beside serotonin-norepinephrine reuptake inhibition:
- Amineptine‡ (Survector, Maneon, Directim) – norepinephrine-dopamine reuptake inhibitor
- Iprindole† (Prondol, Galatur, Tetran) – 5-HT2 receptor antagonist
- Opipramol‡ (Insidon, Pramolan, Ensidon, Oprimol) – σ receptor agonist
- Tianeptine‡ (Stablon, Coaxil, Tatinol) – indirect alteration of AMPA and NMDA glutamate receptor activity
- Trimipramine (Surmontil) – 5-HT2 receptor antagonist and moderate-potency serotonin reuptake inhibitor.
Tetracyclic antidepressants (TeCAs)
- Amoxapine (Asendin)
- Maprotiline (Ludiomil)
- Mianserin (Bolvidon, Norval, Tolvon)
- Mirtazapine (Remeron)
- Setiptiline (Tecipul)
Mianserin, mirtazapine, and setiptiline are also sometimes described as noradrenergic and specific serotonergic antidepressants (NaSSAs).
Monoamine oxidase inhibitors (MAOIs)
- Isocarboxazid (Marplan)
- Phenelzine (Nardil)
- Tranylcypromine (Parnate)
- Selegiline (Eldepryl, Zelapar, Emsam)
- Metralindole (Inkazan)
- Moclobemide (Aurorix, Manerix)
- Pirlindole (Pirazidol)
- Toloxatone (Humoryl)
AntiPsychotics
Excerpted here:
Older or first-generation antipsychotic medications are also called conventional “typical” antipsychotics or “neuroleptics”. Some of the common typical antipsychotics include:
Newer or second-generation medications are also called “atypical” antipsychotics. Some of the common atypical antipsychotics include:
Benzodiazepines
Recommended to wait 7 half-lives after discontinuation before resuming commercial driving: (see MEP report download)
Medications for MS: (from the National Multiple Sclerosis Society)
- Injectable medications
- Oral medications
- Infused medications
- Lemtrada (alemtuzumab)
- Novantrone (mitoxantrone)
- Tysabri (natalizumab)
Parkinson’s Disease
AntiMalaria Drugs
Hydroxychloroquine, mefloquine, atovaquone and proguanil, chloroquine phosphate oral, and quinine may cause dizziness, fatigue, myopathy and weakness, decreased visual accommodation, disturbance in color perception, and visual field defects. Some of these medications contain a warning related to fine motor coordination and decreased alertness and the ability to operate a motor vehicle safely, with a 34% increased crash risk. ref:
Potentially Driver Impairing Medications (requires Medscape login)
Chantix
Causes:
- Accidents and injuries. A total of 173 serious events from falls and traffic accidents, with multiple fracture injuries, from loss of consciousness, mental confusion, dizziness and muscle spasms.
- Vision disturbance. At least 148 reports of vision disturbances, including blurred vision and some forms of blindness.
- Heart rhythm disturbances. The FDA received 224 reports of potential cardiac rhythm disturbances and loss of consciousness.
- Seizures and abnormal muscle spasms or movements. Convulsions (seizures), tremors, muscle spasms, twitching, tics, drooling, and motor hyperactivity.
- Moderate and severe skin reactions. Hives or swelling of the tongue, face, eyes, lips or other areas.
- Diabetes. Loss of glycemic control.
ref: https://naohp.com/wp-content/uploads/Chantix-letter-from-FMCSA.pdf